Literature DB >> 18762561

Primary immune-mediated thrombocytopenia in 30 dogs (1997-2003).

Jutta C Putsche1, Barbara Kohn.   

Abstract

During a 6-year period, primary (idiopathic) immune-mediated thrombocytopenia was retrospectively evaluated in 30 dogs. Ages of the dogs ranged from 3 months to 10 years (median 4 years); female dogs were markedly overrepresented with 73%. Clinical examination revealed hemorrhages in 70% of the dogs. Platelet counts ranged from 0 to 111,000/microL (median 8000/microL); 77% of the dogs had platelet counts <30,000/microL. Seventeen dogs were anemic (hematocrit 9% to 36%; median 31%). Immunosuppressive therapy was performed in all but one dog. The recurrence rate of 19 dogs that were followed over an extended period (112 to 1684 days; median 340 days) was 26%. Twenty-nine (97%) dogs survived 14 days after initial presentation, and 27 (93%) dogs survived at least the following 15 to 1684 days (median 220 days).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18762561     DOI: 10.5326/0440250

Source DB:  PubMed          Journal:  J Am Anim Hosp Assoc        ISSN: 0587-2871            Impact factor:   1.023


  13 in total

1.  In-vitro immunosuppression of canine T-lymphocyte-specific proliferation with dexamethasone, cyclosporine, and the active metabolites of azathioprine and leflunomide in a flow-cytometric assay.

Authors:  Laura A Nafe; John R Dodam; Carol R Reinero
Journal:  Can J Vet Res       Date:  2014-07       Impact factor: 1.310

2.  Pharmacodynamic assessment of ex-vivo canine T-lymphocyte proliferation: Responses to dexamethasone, cyclosporine, mycophenolic acid, and the active metabolite of leflunomide.

Authors:  Megan Grobman; Kaitlin A Bishop; Hansjorg Rindt; Laura A Nafe; Carol R Reinero
Journal:  Can J Vet Res       Date:  2019-10       Impact factor: 1.310

3.  Outcome based on treatment protocol in patients with primary canine immune-mediated thrombocytopenia: 46 cases (2000-2013).

Authors:  Margaret Ann Scuderi; Elizabeth Snead; Susan Mehain; Cheryl Waldner; Tasha Epp
Journal:  Can Vet J       Date:  2016-05       Impact factor: 1.008

4.  An emerging pulmonary haemorrhagic syndrome in dogs: similar to the human leptospiral pulmonary haemorrhagic syndrome?

Authors:  R Klopfleisch; B Kohn; S Plog; C Weingart; K Nöckler; A Mayer-Scholl; A D Gruber
Journal:  Vet Med Int       Date:  2010-12-27

5.  Application of vincristine-loaded platelet therapy in three dogs with refractory immune-mediated thrombocytopenia.

Authors:  Hyung-Jin Park; Ja-Won Kim; Kun-Ho Song; Kyoung-Won Seo
Journal:  J Vet Sci       Date:  2014-09-30       Impact factor: 1.672

6.  Development and implementation of a novel immune thrombocytopenia bleeding score for dogs.

Authors:  Kelly M Makielski; Marjory B Brooks; Chong Wang; Jonah N Cullen; Annette M O'Connor; Dana N LeVine
Journal:  J Vet Intern Med       Date:  2018-04-21       Impact factor: 3.333

7.  Application of therapeutic plasma exchange in dogs with immune-mediated thrombocytopenia.

Authors:  Lucy Kopecny; Carrie A Palm; Sean Naylor; John Kirby; Larry D Cowgill
Journal:  J Vet Intern Med       Date:  2020-06-19       Impact factor: 3.333

Review 8.  Oral cyclosporine treatment in dogs: a review of the literature.

Authors:  T M Archer; D M Boothe; V C Langston; C L Fellman; K V Lunsford; A J Mackin
Journal:  J Vet Intern Med       Date:  2013-12-16       Impact factor: 3.333

9.  Platelet volume and plateletcrit in dogs with presumed primary immune-mediated thrombocytopenia.

Authors:  D Schwartz; L Sharkey; P J Armstrong; C Knudson; J Kelley
Journal:  J Vet Intern Med       Date:  2014-07-23       Impact factor: 3.333

10.  Treatment of 5 dogs with immune-mediated thrombocytopenia using Romiplostim.

Authors:  Barbara Kohn; Gürkan Bal; Aleksandra Chirek; Sina Rehbein; Abdulgabar Salama
Journal:  BMC Vet Res       Date:  2016-06-10       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.